DCM
CARM

Deuterium Capital Management’s Carisma Therapeutics CARM Stock Holding History

Deuterium Capital Management’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-51,256
Closed -$159K – 105
2023
Q1 		$159K Buy
+51,256
New +$488K 0.25% 71

Other funds holding CARM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $104M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Deuterium Capital Management's CARM Position: Q2 2023 in Review

Deuterium Capital Management sold out of Carisma Therapeutics (CARM) in Q2 2023, closing a stake of 51,256 shares — an estimated $159K sold.

Deuterium Capital Management first reported a position in CARM in Q1 2023 and held it in 1 quarter. The position peaked at $159K in Q1 2023. 53 funds tracked by Wall St. Rank hold CARM as of Q2 2023.

  • Deuterium Capital Management reported no remaining Carisma Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Deuterium Capital Management sold 51,256 Carisma Therapeutics shares in Q2 2023, an estimated $159K.
  • Deuterium Capital Management first reported a position in Carisma Therapeutics in Q1 2023 and held it in 1 quarter.
  • Deuterium Capital Management's Carisma Therapeutics position peaked at $159K in Q1 2023.
  • 53 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2023.

Based on Deuterium Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.